医学
胃肠造口术
胃出口梗阻
外科
病因学
临床试验
回顾性队列研究
前瞻性队列研究
癌症
胃切除术
内科学
作者
Andrew Canakis,Monica R. Gaidhane,Haroon M. Shahid,Amy Tyberg,Dillon C. Miller,Romy Bareket,Conan Y. Chen,Petko Ivanov Karagyozov,Avik Sarkar,Jessica L. Widmer,Everson L. Artifon,Prashant S. Kedia,Salil Chowdhury,Divya M. Chalikonda,Vincent Dioguardi,David E. Loren,Thomas E. Kowalski,Alexander Schlachterman,Anand Kumar,Austin Lee Chiang
标识
DOI:10.1097/mcg.0000000000002174
摘要
BACKGROUND: EUS-guided gastroenterostomy (EUS-GE) is a minimally invasive therapy for the management of gastric outlet obstruction (GOO). EUS-GE has demonstrated excellent short-term efficacy without the risks of surgical bypass. However, there is limited data on follow-up outcomes. In this study, we collected 6-month follow-up data on patients who underwent EUS-GE for benign and malignant etiologies, to aim to show the shift in paradigm in their management algorithm. METHODS: This was a retrospective multicenter study across 7 international centers of consecutive patients undergoing EUS-GE over a 4-year period who were entered in a dedicated registry. Demographic characteristics, procedure-related information, and follow-up data were collected. Primary outcome was the 6-month data on clinical resolution of GOO. RESULTS: Ninety-one patients were included (71 malignant and 20 benign cases). Technical success was 99% due to high expertise and volume. Clinical success at 48 hours was 97% (88/90) with an average procedure time of 47 minutes and length of stay of 5.86 days. At 3 months, 87 (95.6%) patients had achieved clinical resolution. At 6 months, 48 (53%) subjects were alive, 40 (44%) were deceased, 3 were lost to follow-up (3.3%) and 1 (1%) had a recurrence of GOO. Clinical success at 6 months follow-up was 98% (47/48). CONCLUSIONS: The majority of patients with GOO who undergo EUS-GE showed clinical resolution at 6-month follow-up. Patients with malignant etiology are appropriately palliated during their life span. Further prospective studies are necessary to obtain long-term data regarding EUS-GE for benign etiologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI